Sarissa’s Healthy Returns Follow Long Activist Campaign

Sarissa founder Alex Denner, who previously worked for Icahn Capital, posted huge gains last year.

Alex Denner (Andrew Harrer/Bloomberg)

Alex Denner

(Andrew Harrer/Bloomberg)

When Novartis completed its $9.7 billion acquisition of The Medicines Company in early January, it capped a more than four-year activist campaign by Sarissa Capital Management to push for changes at the target company.

It was well worth the long effort.

Novartis paid a 45 percent premium for The Medicines Company’s shares, which quadrupled in price last year.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.